Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
| Substantial |
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial. |
Clinical Added Value
| no clinical added value |
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults. |
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
MJMscpkQU6fkUMEp
